Werewolf Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed February 9, 2024, under Item 8.01 (Other Events). The filing concerns an equity offering update under the company’s existing universal shelf registration statement. Werewolf Therapeutics is listed on Nasdaq under the symbol HOWL.
Offering and Key Financial Information
- On February 9, 2024, the company filed a prospectus supplement covering the potential sale of up to $25.0 million of common stock through Leerink Partners LLC under a sales agreement dated May 10, 2022.
- The company previously sold approximately $50.0 million of common stock for aggregate gross proceeds under the sales agreement and prior prospectus.
- Upon filing the new prospectus supplement, the company will no longer offer or sell common stock under the prior prospectus.
- As of January 31, 2024, 40,660,732 shares of common stock were issued and outstanding.
- The filing does not provide revenue, net income or loss, cash flow, margins, debt, cash balances, liquidity runway, or other operating financial metrics.
Material Changes, Outlook, and Risks
The principal change is the replacement of the prior sales agreement prospectus with a new prospectus supplement authorizing up to $25.0 million of additional common-stock offerings. Any sales may dilute existing stockholders and depend on market conditions; the filing does not state how much of the new capacity has been sold or provide a specific sales schedule.
The filing contains no management guidance, operating outlook, clinical update, contingency disclosure, or unusual financial item. Securities may be offered only through the prospectus supplement and applicable registration and securities-law requirements.
Investor Verification Items
- Verify the actual amount and timing of common-stock sales under the new prospectus supplement.
- Assess potential dilution relative to the 40,660,732 shares outstanding as of January 31, 2024.
- Review subsequent filings for net proceeds, offering expenses, cash runway, and use of proceeds.
- Review the related Form S-3, prospectus supplement, sales agreement, and Exhibit 5.1 legal opinion.
- Confirm that the prior prospectus is no longer being used for offers or sales after February 9, 2024.